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Emerging evidence suggests that cancer cell metabolism can be regulated by cancer-
associated fibroblasts (CAFs), but the mechanisms are poorly defined. Here we show that
CAFs regulate malignant cell metabolism through pathways under the control of FAK. In
breast and pancreatic cancer patients we find that low FAK expression, specifically in the
stromal compartment, predicts reduced overall survival. In mice, depletion of FAK in a
subpopulation of CAFs regulates paracrine signals that increase malignant cell glycolysis and
tumour growth. Proteomic and phosphoproteomic analysis in our mouse model identifies
metabolic alterations which are reflected at the transcriptomic level in patients with low
stromal FAK. Mechanistically we demonstrate that FAK-depletion in CAFs increases che-
mokine production, which via CCR1/CCR2 on cancer cells, activate protein kinase A, leading
to enhanced malignant cell glycolysis. Our data uncover mechanisms whereby stromal
fibroblasts regulate cancer cell metabolism independent of genetic mutations in cancer cells.
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Understanding the mechanisms that control malignant cellmetabolism is a major focus of current cancer research.Previous studies have correlated intrinsic genomic and
epigenomic alterations with regulating metabolic features of
cancer cells1,2. Recent work has demonstrated that the tumour
microenvironment, particularly cancer-associated fibroblasts
(CAFs), is important in regulating cancer cell metabolism mostly
via the production of metabolites that affect cancer cells3. How-
ever, in vivo evidence dissecting the molecular mechanisms by
which CAFs regulate malignant cell metabolism in different
tumour models is still required.
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor
protein tyrosine kinase and is ubiquitously expressed. Many
reports indicate that FAK overexpression in bulk tumour analyses
is associated with poor prognosis4,5 and these results have spur-
red the development of FAK inhibitors for cancer treatment.
However, other reports suggest either no correlation with prog-
nosis or even that low FAK expression is associated with poor
prognosis6,7. None of these clinical analyses separate the pre-
dictive significance of stromal FAK expression. In mice, genetic
dissection of the effect of FAK loss in separate compartments of
the tumour stroma have indicated that loss of endothelial cell
FAK can affect the initiation of tumour angiogenesis and function
depending on the temporal regulation of EC-FAK depletion8,9.
Additionally, heterozygous depletion of FAK can enhance tumour
angiogenesis and tumour growth while loss of haematopoetic
FAK can enhance cancer metastasis without an apparent effect on
primary tumour growth10. The impact of these studies lies in
elucidating the multiple functions of FAK in different stromal cell
types in the control of cancer growth.
Several reports indicate that fibroblast FAK can induce cell
motility, extracellular matrix deposition, survival and prolifera-
tion via several signalling pathways in vitro11,12 suggesting that
FAK expression in CAFs is required for these functions in vivo. In
addition to these functions, previously published work has shown
that FAK can regulate the production of different chemokines
and cytokines depending on the cell type and experimental
settings9,13–15.
Here, we address the role of FAK in CAFs and show that it
regulates tumour cell metabolism by paracrine cytokine signal-
ling. We find that loss of FAK in a subpopulation of CAFs is
sufficient to induce increased tumour growth and enhance
malignant cell glycolysis. These observations are validated in
human breast and pancreatic cancers with low stromal FAK
expression. Mechanistically, loss of FAK in a subpopulation of
CAFs causes the enrichment of cytokine signalling pathways and
the upregulation of Ccl6, Ccl11, Ccl12 and pentraxin-3 resulting
in the enhancement of glycolysis in malignant cells. Thus, our
study reveals a mechanism of malignant cell metabolism that
involves expression of FAK in CAFs.
Results
Low FAK expression in the stromal compartment is associated
with poor survival in human breast and pancreatic cancers.
Increased involvement of stromal CAFs is a pathophysiological
feature associated with both breast and pancreatic ductal ade-
nocarcinoma progression but the role of CAF-FAK in progression
of these cancers has not been addressed before. Here we per-
formed multivariate analysis of human breast16 and pancreatic
cancer17,18 datasets, and found that low stromal FAK expression
in both these cancer types is associated with reduced overall
survival (Fig. 1a, b, Supplementary Fig. 1). Given that CAFs
represent the major cellular component of the tumour stroma,
these data led us to investigate the functional role of low FAK
expression in CAFs in cancer growth.
Development and characterisation of a mouse model of FAK-
deletion in CAFs. CAFs are heterogeneous populations of cells
and thus no one marker identifies all CAFs19,20 To develop a
genetic tool to assess if stromal FAK could regulate tumour
growth and progression, we used Cre-Lox recombination to delete
FAK in the FSP-1-positive subpopulation of CAFs21. Please see
Methods section for justification for using FSP-Cre+ mice from
Gustavo Leone’s laboratory. FSP-Cre+;FAKfl/fl and FSP-Cre−;
FAKflf/fl mice were born at normal Mendelian ratios, and showed
no defects in weight, gender distribution and tissue morphology
(Supplementary Fig. 2a, b). Primary lung fibroblasts isolated from
these mice did not express epithelial and endothelial markers, but
did express common markers of fibroblasts, namely, PDGFR-β
and FSP-1 (Supplementary Fig. 2c, Supplementary Fig. 7). CAF-
specific FAK depletion was confirmed by the following: epithelial
cells isolated from breast tumours grown in MMTV+;FSP-Cre+;
FAKfl/fl or MMTV+;FSP-Cre−;FAKfl/fl mice had no detectable
differences in FAK expression levels (Supplementary Fig. 2d,
Supplementary Fig 7); using CAG-tdTomato reporter mice, the
vast majority (94.8%) of tdTomato-positive cells are CD45 nega-
tive (Supplementary Fig. 2e); depletion of FAK was not observed
in BMDMs in FSP-Cre+;FAKfl/fl mice (Supplementary Fig. 2f, g,
Supplementary Fig 7). Additionally, FSP-1 expression was barely
detectable in normal lung fibroblasts from both FSP-Cre+;FAKfl/fl
and FSP-Cre−;FAKfl/fl mice, and its expression was significantly
increased after fibroblast activation with a corresponding reduc-
tion of FAK only in fibroblasts from FSP-Cre+;FAKfl/fl mice
(Supplementary Fig. 2h). Previous reports have indicated that
FAK expression can affect the expression of the closely related
kinase Pyk2 (refs. 22–25) but that compensation is not always
evident and depends on the experimental setting8,24,26. Here we
show that Pyk2 expression was not affected in activated fibroblasts
from FSP-Cre+;FAKfl/fl mice (Supplementary Fig. 2h, Supple-
mentary Fig 7). Moreover, depletion of FAK expression was
demonstrated in primary CAFs from MMTV+;FSP-Cre+;FAKfl/fl
mice in vitro and orthotopic pancreatic tumours in vivo (Sup-
plementary Fig. 2i, j, Supplementary Fig 7). Together with pub-
lished evidence for CAF specificity in FSP-Cre+mice21,27, our data
support depletion of FAK in a subpopulation of CAFs in these
FSP-Cre+;FAKfl/fl mice.
FSP-Cre+;FAKfl/fl mice display increased breast and pancreatic
cancer growth. To examine the effects of FAK depletion in FSP-
1-positive CAFs on primary tumour growth, syngeneic orthotopic
breast and pancreatic cancer growth was assessed using E0771
and TB32048 cells, respectively. Enhanced tumour growth was
observed in FSP-Cre+;FAKfl/fl mice for both tumour types.
Additionally, these results were supported by an increase in the
number of tumours per mouse in MMTV+;FSP-Cre+;FAKfl/fl
mice compared with controls at week 16 (Fig. 1c, Supplementary
Fig. 2k, l). Orthotopic tumour growth was not different in FSP-
Cre+;non-floxed vs FSP-Cre−;non-floxed mice indicating that
Cre expression alone had no effect (Supplementary Fig. 2m).
Together, these data demonstrate that depletion of FAK in FSP-1-
positive CAFs is sufficient to enhance tumour growth and disease
progression.
We next assessed whether possible changes in components of
the tumour microenvironment could inform a cellular basis of the
enhanced tumour growth in FSP-Cre+;FAKfl/fl mice. Tumour
desmoplasia was assessed by Picrosirius red staining, an indicator
of collagen deposition, in late-stage E0771 and TB32048 tumours
grown in FSP-Cre+;FAKfl/fl, MMTV+;FSP-Cre+;FAKfl/fl and
control mice. Collagen deposition was unchanged in orthotopic
tumours and modestly reduced in breast tumours fromMMTV+;
FSP-Cre+;FAKfl/fl mice (Fig. 1d). These data suggest that FAK
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expression in FSP-1-positive subpopulation of CAFs has little
effect on tumour desmoplasia. This suggests that the increased
tumour growth and progression in FSP-Cre+;FAKfl/fl mice does
not appear to depend on major changes in desmoplasia. Another
component of the tumour stroma is the immune infiltrate and
tumour-associated macrophages (TAMs) are known to facilitate
tumour growth28. Unexpectedly, a significant reduction in TAMs
was found in late-stage orthotopic breast and pancreatic tumours
grown in FSP-Cre+;FAKfl/fl mice, as well as MMTV+;FSP-Cre+;
FAKfl/fl mice, compared with control mice whilst no difference
was detected in early-stage tumours (Supplementary Fig. 3a–c).
No differences were observed in the total numbers and activation
of T-lymphocytes, or numbers of B-lymphocytes, dendritic cells
and granulocytes (Supplementary Fig. 3d–e). Several studies have
indicated that enhanced angiogenesis can induce tumour growth
and CAFs are linked to angiogenesis29. Thus, we examined blood
vessel density and hypoxia in age- and size-matched tumours
grown in FSP-Cre+;FAKfl/fl and FSP-Cre−;FAKfl/fl mice. We
showed that blood vessel density was surprisingly decreased with
a corresponding increase in tumour hypoxia in both E0771 and
TB32048 late-stage tumours (Fig. 2a, b). Given that the number of
tumour blood vessels alone is not necessarily indicative of
vascular function, we also showed that the perfusion of the
tumour blood vessels in FSP-Cre+;FAKfl/fl and FSP-Cre−;FAKfl/fl
mice is similar (Fig. 2c, d). These data indicate that the enhanced
tumour growth observed in FSP-Cre+;FAKfl/fl mice was not due
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to increased tumour angiogenesis or blood vessel perfusion. To
address whether this reduction in blood vessel density was a
constitutive feature of tumours grown in FSP-Cre+;FAKfl/fl mice,
we also examined blood vessel density and hypoxia in early stage,
size-matched tumours before the tumour growth diverged
significantly between the genotypes. At this stage, both blood
vessel density and tumour hypoxia were unchanged in E0771 and
TB32048 tumours (Fig. 2e, f). Together, these data suggest that
depletion of CAF-FAK enhances tumour growth despite reduced
numbers of blood vessels.
FAK depletion in CAFs enhances malignant cell metabolism.
Cancer cells undergo metabolic changes to support tumour
growth and proliferation under harsh environmental conditions1.
Given the enhanced tumour growth despite reduced blood vessel
density, we examined whether the loss of CAF-FAK influenced
malignant cell metabolism. 18F-FDG-PET/CT imaging of mice
with early-stage, size-matched orthotopic breast tumours, which
had a similar proliferation index (Supplementary Fig. 4a, b),
showed significantly higher SUVmax values indicating a potential
increase in glucose uptake in tumours grown in FSP-Cre+;FAKfl/fl
mice (Fig. 3a). In line with this result, we detected increased levels
of labelled glucose upon infusion of tumour-bearing mice with
[U-13C6] glucose (Fig. 3b). Further, liquid chromatography-mass
spectrometry (LC-MS) analysis demonstrated that in addition to
increased lactate levels, glucose significantly increased its con-
tribution to tricarboxyclic acid (TCA) cycle in orthotopic breast
tumours. Percentages of labelled isotopologues of TCA cycle
intermediates succinate, fumarate and malate as well as aspartate
and glutamate were all increased significantly in tumours grown
in FSP-Cre+;FAKfl/fl mice (Fig. 3c). Although the increase in
lactate levels was not statistically significant, similar findings were
detected for TCA cycle intermediates as well as aspartate and
glutamate in orthotopic pancreatic tumours grown in FSP-Cre+;
FAKfl/fl mice. Furthermore, levels of labelled isotopologues of
orotate and uracil were elevated indicating an increase in pyr-
imidine biosynthesis (Supplementary Fig. 4c). Importantly, these
data identified that depletion of FAK in the FSP-1 expressing
subpopulation of CAFs alters glucose metabolism in tumours
in vivo even before tumour growth rates significantly diverged
between FSP-Cre+;FAKfl/fl and FSP-Cre−;FAKfl/fl mice.
Since LC-MS analysis was performed on whole-tumour
extracts, in order to dissect metabolic alterations in different cell
types and elucidate the cellular and molecular mechanisms that
underlie how reduced expression of CAF-FAK could regulate the
metabolism of malignant cells, we compared primary tumour
cells from MMTV+;FSP-Cre−;FAKfl/fl and MMTV+;FSP-Cre+;
FAKfl/fl mammary tumours by Seahorse Extracellular Flux
analysis. Freshly isolated malignant cells from MMTV+;FSP-
Cre+;FAKfl/fl mice had elevated glycolysis and glycolytic capacity
when compared with freshly isolated malignant cells from
controls (Fig. 3d). Furthermore, these metabolic alterations were
lost when primary malignant cells were cultured for 3 days (Fig. 3
e), supporting the idea that the enhanced glycolysis and glycolytic
capacity in freshly isolated malignant cells were due to
microenvironmental signals. On the other hand, primary CAFs
isolated from MMTV+;FSP-Cre+;FAKfl/fl and MMTV+;FSP-Cre
−;FAKfl/fl mice showed no differences in glycolysis and glycolytic
capacity (Fig. 3f). FAK-kinase inhibitor treated WT-CAFs also
showed no apparent effect on glycolysis (Fig. 3g). Additionally,
FAK-depleted CAFs had increased basal respiration and ATP
production when compared with WT-CAFs (Supplementary
Fig. 4d), suggesting that they are not primarily supporting tumour
cells through lactate to drive increased mitochondrial oxidative
phosphorylation30. Effects on CAF OCR were also observed when
WT-CAFs were treated with the FAK-inhibitor PF-573, 228
(Supplementary Fig. 4e), suggesting that these effects involved the
kinase activity of FAK.
Supporting the enhanced malignant cell metabolism described
above, proteomics/phosphoproteomics analysis revealed that
cellular response to oxidative stress, electron transport chain,
glycolysis, fatty acid biosynthesis, CTP and UTP biosynthesis
were significantly enriched in primary mouse epithelial cells
exposed to FAK-depleted CAF CM (Fig. 4a). Total proteomics
analysis revealed a significant increase in the abundance of two
key enzymes in the oxidative branch of pentose phosphate
pathway (PPP), glucose-6-phosphate dehydrogenase (G6PD) and
6-phosphogluconate dehydrogenase (6PGD) in cancer cells
exposed to FAK-depleted CAF CM. PPP is an important source
of redox cofactor NADPH and ribonucleotides31. Several other
glycolytic enzymes, including pyruvate kinase, aldolase, enolase,
glycerol 3-phosphate dehydrogenase (GPD), glyceraldehyde 3-
phosphate dehydrogenase (GAPD) and phosphoenolpyruvate
carboxykinase (PCK), were also elevated (Fig. 4b). Importantly,
these changes were validated in the increases of these enzymes at
the RNA level in breast cancer patients with low stromal FAK
(Fig. 4b, box and whisker graphs). Relevant to the enhanced TCA
cycle and electron transport chain, proteomics analysis of mouse
epithelial cells exposed to FAK-depleted CAF CM also revealed
upregulation of IDH as well as malate dehydrogenase (MDH) 1
and 2 and ATP5B (Fig. 4c, box and whisker graphs). Indeed,
isocitrate dehydrogenase (IDH), succinate dehydrogenase (SHD),
fumarate hydratase (FH) and ATP5B were all upregulated in
Fig. 1 Cancer-associated fibroblast FAK depletion enhances tumour growth. Low stromal FAK expression is significantly associated with reduced overall
survival in a human breast (microdissected tumour stroma analysis from 53 primary breast tumours, Finak et al. dataset) and b human pancreatic cancers
(54 human pancreatic cancers with activated stroma, Stratford et al. dataset). The Cox proportional hazards (Coxph) regression analysis was performed,
with the rank P value shown. See full details in Methods “Gene expression data analysis and clinical inferences” section. c Tumour growth is enhanced in
FSP-Cre+; FAKfl/fl mice. FSP-Cre+; FAKfl/fl and control FSP-Cre−;FAKfl/fl mice were injected orthotopically with either syngeneic breast cancer cells (E0771,
n= 10 FSP-Cre+; FAKfl/fl mice and n= 18 FSP-Cre−;FAKfl/fl mice) or pancreatic ductal adenocarcinoma cells (TB32048, n= 10 FSP-Cre+; FAKfl/fl mice and
11 FSP-Cre−;FAKfl/fl mice). FSP-Cre+; FAKfl/fl and FSP-Cre−; FAKfl/fl mice were also crossed with MMTV-PyMT mice to generate MMTV+;FSP-Cre+;FAKfl/fl
and MMTV+;FSP-Cre−;FAKfl/fl mice that developed spontaneous breast tumours. E0771 and TB32048 tumour growth was enhanced in FSP-Cre+;FAKfl/fl
mice and the number of tumours per mouse increased significantly in MMTV+;FSP-Cre+;FAKfl/fl when compared with control mice. n= 11 MMTV+; FSP-
Cre+;FAKfl/fl and 8 MMTV+;FSP-Cre−;FAKfl/fl mice. Graphs represent mean tumour volume ± s.e.m. Bar chart represents mean no. tumours per mouse ± s.
e.m. d Picrosirius red staining of late-stage tumour sections from E0711, TB32048 and MMTV-PyMT tumours in FSP-Cre+; FAKfl/fl and FSP-Cre−; FAKfl/fl
mice. Scatter plots represent picrosirius red image analysis (ImageJ) for individual tumours. n= 6 FSP-Cre−; FAKfl/fl and 7 FSP-Cre+; FAKfl/fl E0771
tumours; n= 14 FSP-Cre−; FAKfl/fl and 15 FSP-Cre+; FAKfl/fl TB32048 tumours; n= 8 FSP-Cre−; FAKfl/fl and 6 FSP-Cre+; FAKfl/fl MMTV tumours. Bar chart
represents mean ± s.e.m. *P < 0.05, ***P < 0.001. nsd no significant difference. Statistical analysis, two-way ANOVA (c for E0771 and TB32048 growth
curves); two-sided Student’s t-test (c for MMTV data, ***P < 0.0002 and d *P < 0.05). Scale bars, 1 cm (c); 100 μm (d).
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human breast cancers with low stromal FAK (Fig. 4c). Similarly, a
significant upregulation in the transcription of genes encoding
enzymes, which are involved in fatty acid metabolism, were also
observed in breast cancer patients and our mouse model (Fig. 4d).
Further GSEA of the epithelial compartment using Reactome
database identified enrichment in crucial processes for tumour
growth and disease progression, such as synthesis of DNA,
protein synthesis and cell cycle progression in addition to major
metabolic pathways (Fig. 4e). GSEA confirmed significant
upregulation of various metabolic pathways, TCA cycle in
particular, in the epithelial cell compartment of low-FAK stromal
patients using KEGG biological pathways as well (Supplementary
Fig. 5a). Together, these data corroborate that low stromal FAK
expression regulates malignant cell metabolism in both human
and mouse tumours and substantiate the clinical relevance of our
findings.
CAFs control malignant cell metabolism through chemokines
Ccl6 and Ccl12. We next examined the paracrine mechanism(s)
by which CAF-derived signals could affect malignant cell meta-
bolism. Tumour cells, exposed to FAK-depleted CAF CM (48 h),
displayed significantly enhanced glycolysis, glycolytic capacity
and glycolytic reserve (Fig. 5a) suggesting a paracrine signal from
CAFs to malignant cells was sufficient to control malignant cell
glycolysis. Reducing the exposure time to 2 h was still sufficient to
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enhance glycolytic capacity and reserve. However, upon heat
inactivation of the conditioned medium, these metabolic altera-
tions were abolished (Fig. 5b), indicating that CAF-FAK regulates
the production of proteinaceous factors that can alter cancer cell
metabolism. Although these findings would not completely
exclude the potential contribution of CAF-derived metabolites,
total rescue of metabolic alterations in cancer cells prompted us
to focus on the proteome of the CAFs. Proteomics analysis of the
primary CAFs revealed a significant enrichment of PI3K and
cytokine-mediated signalling pathways in FAK-depleted CAFs
(Fig. 5c). Comparison of the secretomes using cytokine arrays
(mouse proteome profiler dot blot arrays) showed that Ccl6,
Ccl11, Ccl12 and Pentraxin-3 were significantly upregulated in
FAK-depleted CAFs (Fig. 5d, Supplementary Fig. 5b, c). Addi-
tionally, an increase in Ccl6 and Ccl12 mRNA was observed in
FAK-depleted CAFs (Fig. 5e), and further analysis for chemo-
kines, which were not present in the array, revealed that two other
CC chemokines, Ccl7 and Ccl8, were also transcriptionally
upregulated in FAK-depleted CAFs (Supplementary Fig. 5d). In
vivo evidence of this upregulation of chemokines was also found
since Ccl6 and Ccl12 transcript levels were upregulated in FSP-1-
positive CAFs in tumour sections from MMTV+;FSP-Cre+;
FAKfl/fl compared with control mice, demonstrating their reg-
ulation by CAF-FAK in vivo (Fig. 5f). Human orthologues of
mouse Ccl6 and Ccl7, namely CCL23 (ref. 32) and CCL7,
respectively, were shown to be inversely correlated with stromal
FAK expression in breast cancer patients providing human rele-
vance of our findings (Fig. 5g, Supplementary Fig. 5e).
FAK has both kinase and scaffolding functions and FAK-
kinase inhibitors are currently being tested in clinical trials for
cancer treatment raising the question as to whether such
inhibitors might affect chemokine production in CAFs. Treat-
ment of WT-CAFs with the FAK-kinase inhibitor, PF-573,228,
was sufficient to enhance Ccl6, Ccl11 and pentraxin protein
expression levels but to a lesser extent than found in FAK-
depleted CAFs. However, Ccl12 protein expression levels were
not increased by inhibition of FAK kinase activity suggesting that
other non-kinase FAK-mediated mechanisms control this
chemokine (Supplementary Fig. 5f). Indeed, FAK-kinase inhibi-
tion was sufficient to enhance Ccl6, but not Ccl12, transcription in
WT-CAFs. Given that the PI3K signalling pathway is significantly
upregulated in FAK-depleted CAFs and this pathway has been
previously shown to influence the production of inflammatory
cytokines33, we assessed Ccl12 mRNA levels in FAK-depleted
CAFs after treatment with the pan-class I PI3K inhibitor GDC-
0941. PI3K inhibition significantly downregulated Ccl12 tran-
scription compared with untreated FAK-depleted CAFs suggest-
ing that Ccl12 and Ccl6 expression are likely regulated by different
mechanisms (Supplementary Fig. 5g). Together, these data
indicate that FAK depletion in CAFs can increase the expression
of several chemokines and suggest that chemokine regulation
involves both FAK-kinase and non-kinase mediated mechanisms.
FAK depletion in CAFs increases chemokine production,
which via CCR1/CCR2 on cancer cells, activate protein kinase
A, leading to enhanced malignant cell glycolysis. To examine
the molecular mechanisms that control elevated metabolism in
malignant cells exposed to a FAK-depleted CAF environment, we
turned our attentions to signalling downstream of chemokine
stimulation and especially Ccl6 and Ccl12 since these were the
most highly upregulated. The functional roles of Ccl6 and Ccl12
in the regulation of malignant cell metabolism were supported by
several lines of evidence. Firstly, the addition of recombinant Ccl6
and Ccl12 to the culture medium of breast tumour cells was
sufficient to enhance their glycolytic capacity (Fig. 6a) supporting
the notion that these chemokines are capable of altering malig-
nant cell metabolism. Secondly, in order to test whether the
receptors for these chemokines, namely CCR1 and CCR2 (ref. 34),
are involved in regulating cancer cell metabolism, malignant cells
fromMMTV+;FSP-Cre−;FAKfl/fl mice were exposed to WT-CAF
CM, FAK-depleted CAF CM or FAK-depleted CAF CM with
inhibitors to these receptors, CCR1i/CCR2i, or vehicle alone.
Results revealed that the addition of CCR1i/CCR2i into WT-CAF
CM had no effect on cancer cell metabolism (Fig. 6b), likely
because WT-CAFs did not have high levels of expression of Ccl6
or Ccl12. In contrast, the enhanced glycolytic capacity and gly-
colytic reserve in cancer cells exposed to FAK-depleted CAF CM
were significantly reduced by treatment with CCR1i/CCR2i
(Fig. 6c). Thirdly, siRNA knockdown of CCR1 and CCR2 in
E0771 breast cancer cells had no significant effect on metabolism
under normal culture conditions, but significantly inhibited gly-
colytic capacity and glycolytic reserve when malignant cells were
exposed to FAK-depleted-CAF CM, but not WT-CAF CM
(Supplementary Fig. 5h, Fig. 6d). These data suggested that
pharmacological or genetic depletion of CCR1 and CCR2 do not
affect breast cancer cell metabolism under normal culture con-
ditions but only after exposure to FAK-depleted CAF CM.
Fig. 2 Depletion of CAF-FAK reduces tumour blood vessel density in late stage tumours. Histological analysis of blood vessel density and hypoxia in
size-matched, age-matched late stage a E0771 (day 34) and b TB32048 (Day 33) tumours grown in FSP-Cre+; FAKfl/fl and FSP-Cre−; FAKfl/fl mice.
Tumours were sectioned and immunostained for either endomucin or pimonidazole and the number of blood vessels or relative areas of hypoxia quantified
across whole-tumour sections. A significant reduction in blood vessel density and increase in hypoxia were observed in late-stage tumours from FSP-Cre+;
FAKfl/fl mice. Bar charts show quantitation of mean blood vessel density per mm2 ± s.e.m. and mean pimonidazole positive area fraction ± s.e.m (n= 5
(E0771) and 9 (TB32048) FSP-Cre−; FAKfl/fl and 6 (E0771) and 10 (TB32048) FSP-Cre+; FAKfl/fl tumours, for endomucin; n= 5 FSP-Cre−; FAKfl/fl and FSP-
Cre+; FAKfl/fl E0771 tumours and 6 FSP-Cre−; FAKfl/fl and 5 FSP-Cre+; FAKfl/fl TB32048 tumours, for pimonidazole). c, d Blood vessel perfusion was
measured by calculating the percentage of endomucin-positive blood vessels that were PE-PECAM positive. The functionality of tumour blood vessels was
assessed by immunofluorescence staining of endomucin in mice perfused with PE-PECAM antibody on late-stage c E0771 breast and d TB32048
pancreatic tumour sections. The percentage of perfused blood vessels was not different between the two genotypes. Bar charts show mean percentage of
perfused vessels (double positive) over total number of blood vessels (endomucin positive). n= 3 tumours from FSP-Cre−;FAKfl/fl and 3 tumours from FSP-
Cre+;FAKfl/fl mice. Arrows, representative perfused vessels. Green: endomucin, red: PE-PECAM. Bar chart in c and d represents mean % perfused blood
vessels ± s.e.m; two-sided Student’s t-test. nsd no significant difference. Scale bars, 25 μm. e, f Before tumour growth diverged significantly between
genotypes, early stage, size-matched E0771 breast (day 21) and TB32048 pancreatic (day 21) tumours were also analysed for tumour angiogenesis (E0771:
n= 6 tumours/genotype; TB32048: n= 6 tumours from FSP-Cre−;FAKfl/fl and 5 tumours from FSP-Cre+;FAKfl/fl mice) and hypoxia (E0771: n= 4 tumours/
genotype; TB32048: n= 6 tumours from FSP-Cre−;FAKfl/fl and 5 tumours from FSP-Cre+;FAKfl/fl mice) as above. No changes in blood vessel density
or hypoxia were detected at this early stage of tumour growth. Bar chart in e and f shows mean blood vessel density per mm2 ± s.e.m. Scale bars in
a, b, e, f for endomucin, 25 μm; pimonidazole, 200 μm. For a and b, *P < 0.05, **P < 0.01. nsd, no significant difference. Statistical analysis, two-sided
Student’s t-test.
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Indeed, CCR1i/CCR2i treatment had no effect on tumour burden
in FSP-Cre−;FAKfl/fl mice compared with untreated or vehicle
alone treated FSP-Cre−;FAKfl/fl mice. In contrast, CCR1i/CCR2i
treatment significantly reduced the elevated tumour burden in
FSP-Cre+;FAKfl/fl mice down to those in FSP-Cre−;FAKfl/fl
control mice (Fig. 6e). These results correlated with a rescue in
the metabolic phenotype in these tumours, where LC-MS analysis
demonstrated that treatment of FSP-Cre+;FAKfl/fl mice with
CCR1i/CCR2i reduced bulk tumour metabolite levels down to
those found in vehicle-treated FSP-Cre−;FAKfl/fl control mice
(Fig. 6f). Of note, CCR1 and CCR2 are members of the family of
G-protein coupled receptors (GPCR)35 and enhanced GPCR
signalling through Gαs and Gα12/13 was also observed in the
epithelial compartment of patient tumours with low stromal FAK
correlating low stromal FAK expression, cancer progression,
enhanced metabolism with elevated signalling via GPCRs in
human cancer (see Fig. 4e). Together, these cross-supporting data
provide evidence that CCR1 and CCR2 are functionally involved
in the enhanced glycolysis of cancer cells after exposure to a FAK-
depleted CAF environment.
It has been reported that CCR1 and CCR2 can influence the
myeloid infiltrate36,37. The reduction in TAMs in late-stage
tumours in FSP-Cre+;FAKfl/fl mice prompted us to investigate
the metabolic phenotype of these cells. Although BMDMs from
non-tumour-bearing FSP-Cre+;FAKfl/fl and control mice show
no differences in metabolism, BMDMs from tumour-bearing
MMTV+;FSP-Cre+;FAKfl/fl mice display significantly elevated
glycolysis and glycolytic capacity compared with those from
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MMTV+;FSP-Cre−;FAKfl/fl mice (Supplementary Fig. 6a, b).
Furthermore, exposure of BMDMs to FAK-depleted CAF CM for
3 h increased glycolytic capacity and glycolytic reserve signifi-
cantly (Supplementary Fig. 6c) suggesting that although FAK-
depleted CAF CM is sufficient to induce modest metabolic
alterations in macrophages, tumour cell-derived factors are very
likely involved in enhanced glycolysis in BMDMs upon depletion
of FAK in CAFs.
Further investigation of the molecular control of malignant cell
metabolism regulation, using Kinase Substrate Enrichment Analysis
(KSEA)38 in cancer cells exposed to FAK-depleted CAF-CM,
identified substrate enrichment in multiple signalling pathways that
included protein kinase A catalytic subunit α (PKACA), PKD1,
p38δ, p90RSK, smMLCK, ROCK2, PAK4, DAPK3, DAPK1 and
p38α, all known to be involved, directly or indirectly, in enhanced
cell metabolism (Fig. 6g). Although many chemokine receptors are
coupled to Gαi subunit, which inhibits adenylate cyclase activity and
cAMP production35, we detected enrichment of PKA substrates.
For example, PKD1, a substrate of PKA39, stimulates p42/44 MAPK
(Ras–Raf–MEK–Erk) signalling pathway40 subsequently enhancing
p90RSK, an important regulator of protein synthesis41 and
glycolysis42. Stress activated p38MAPK signalling pathway was also
upregulated in cancer cells through p38α and p38δ, which is known
to be involved in glucose metabolism through PKD143. Addition-
ally, substrates for PAK4 (p21(RAC1) activated kinase 4), a
regulator of glucose intake, NADPH production and lipid synthesis
through its interaction with glucose-6-phosphate dehydrogenase
(G6PD)44 and ROCK2 were also enhanced. ROCK2 is downstream
of RhoA from Rho family of GTPases and is activated through
coupling of G proteins to Rho guanine nucleotide exchange
factors45. KSEA analysis identified similar substrate enrichment for
Ca2+/calmodulin-dependent serine threonine kinases MLCK and
DAPK1 (Fig. 6g) supporting the activation of GPCR signalling. A
direct link between these kinases, which are mainly involved in
cystoskeletal remodelling, and cellular metabolism has not been
identified to date. Additionally, stimulation of GCPRs can result in
the release of Ca2+ from intracellular stores through the generation
of diacylglycerol and inositol 1,4,5-triphosphate (IP3)46. IP3 receptor
ITPR3 phosphorylation at serine 1832 residue, which is a PKA
phosphosite47, was enhanced in cancer cells treated with CAF-
depleted CM in addition to calmodulin and phosphorylated
calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2).
Ca2+/calmodulin/CaMKK2 axis also influences glucose and lipid
metabolism48 (Supplementary Fig. 5i). Wnt/beta-catenin signalling
regulates metabolic reprogramming in the cancer cells as it
upregulates cMyc expression in a TCF-dependent manner49. We
observed enhanced phosphorylation of beta-catenin at PKA site
serine 552 that promotes TCF/LEF transactivation50 (Supplemen-
tary Fig. 5i). Additionally, phosphoCTNNA1(alpha-catenin)(serine
641) was additionally upregulated supporting beta-catenin transac-
tivation51. In line with the integration of JAK/STAT and G protein
pathways upon chemokine exposure, total STAT3 and phospho-
STAT3 (Y705) levels were enhanced in cancer cells exposed to
FAK-depleted CAF CM52 (Supplementary Fig. 5i). The JAK/STAT3
pathway is also a known mediator of glucose53 and fatty acid
metabolism54. The clinical relevance of these signalling changes was
demonstrated by the elevated transcription of genes encoding the
regulatory subunit of PKA (PRKAR1A), Rap1A, Kinase suppressor
of Ras (KSR), MAP2K3 (MKK3), small GTPase Rac1, CTNBB1
(beta-catenin) and LEF1 in the epithelial compartment of human
breast cancers with low levels of stromal FAK (Fig. 6 h). While
Rap1-KSR interaction downstream of PKA sustains Erk activa-
tion55, MAP2K3 (ref. 56) is important for the activation of p38
MAPKs. Together, these data identify several putative metabolism
regulatory pathways that are enhanced in cancer cells exposed to a
FAK-depleted CAF environment.
Since PKA can interact with many signalling alterations directly
or indirectly observed in phosphoproteomics analysis, we treated
malignant cells isolated fromMMTV+;FSP-Cre−;FAKfl/fl mice with
conditioned medium from FAK-depleted CAFs plus or minus a
pharmacological inhibitor of PKA (KT 5720) for the functional
validation of these signalling changes. Seahorse analysis demon-
strated that PKA inhibition was sufficient to reduce the enhanced
glycolytic capacity and glycolytic reserve of malignant cells exposed
to FAK-depleted CAF CM back to that of vehicle-treated cancer
cells after exposure to conditioned medium from WT-CAFs
(Fig. 6i). DAG and intracellular calcium release enhances protein
kinase C activity upon activation of GPCRs. Since PKA and PKC
signalling may converge through common downstream effectors,
we also tested the effect of PKC inhibition on the same metabolic
parameters. Addition of PKC inhibitor (Go6983) to the CM, at a
concentration of 10 μM, which inhibits PKCα, β,γ, δ isoforms, did
not rescue the enhanced glycolytic capacity and reserve (Supple-
mentary Fig. 6d). Although pharmacological inhibitors can have
off-target effects, the validation of the specificity and the efficacy of
the pharmacological inhibitors used in this study are provided
(Supplementary Fig. 6e–h, Supplementary Fig 7).
Together, our data indicate that the elevated production of
Ccl6 and Ccl12 from FAK-depleted CAFs activates chemokine
receptors CCR1 and CCR2 on malignant cells altering the
regulation of downstream signals that control malignant cell
metabolism. Indeed, the enhanced activation of malignant cell
PKA after exposure to FAK-depleted CAF CM is required for the
upregulation of malignant cell metabolism.
Fig. 3 FAK depletion in FSP-1 positive CAFs alters malignant cell metabolism. a 18F-FDG PET/CT imaging of early-stage, size-matched E0771 orthotopic
breast tumours revealed enhanced glucose uptake in tumours grown in FSP-Cre+;FAKfl/fl mice when compared with controls. PET images expressed on the
same scale, range= 0–7 SUV. Bar charts show mean maximum standardised uptake value (SUVmax) ± s.e.m. n= 6 FSP-Cre−;FAKfl/fl and 9 FSP-Cre+;
FAKfl/fl mice. b, c FSP-Cre+; FAKfl/fl and FSP-Cre−; FAKfl/fl mice bearing early-stage, size-matched E0771 tumours were continuously infused with [U-13C6]
glucose and LC-MS analysis of metabolites extracted from tumours. Results showed b an increase in M+6 isotopologue of glucose, with c an enrichment of
isotopologues of lactate, succinate, fumarate, malate, aspartate and glutamate from tumours grown in FSP-Cre+;FAKfl/fl mice. Bar charts show mean % of
the indicated isotopologue pool over the total metabolite pool ± s.e.m. n= 7 FSP-Cre−;FAKfl/fl and 9 FSP-Cre+; FAKfl/fl tumours. d Seahorse extracellular
flux analysis of freshly sorted EpCAM+ malignant cells from tumours grown in MMTV+;FSP-Cre+;FAKfl/fl mice showed enhanced glycolysis and a
significant increase in glycolytic capacity compared with control mice. Bar charts show mean ECAR ± s.e.m. n= 3 independent experiments; n= 8MMTV+;
FSP-Cre−;FAKfl/fl and 5 MMTV+;FSP-Cre+;FAKfl/fl cell technical repeats from a representative run. e The changes in glycolysis and glycolytic capacity were
lost when malignant cells isolated from MMTV+;FSP-Cre+;FAKfl/fl and control mice were isolated and cultured for 3 days; n= 3 independent experiments,
n= 6 MMTV+;FSP-Cre−;FAKfl/fl and 4 MMTV+;FSP-Cre+;FAKfl/fl cell technical repeats from the representative run. f Primary FAK-depleted and WT-CAFs
have similar glycolysis and glycolytic capacity; n= 4 independent experiments, 4 technical repeats for each genotype from the representative run. g WT-
CAFs treated with vehicle alone or FAK-kinase inhibitor (PF PF-573,228) have similar levels of glycolysis. n= 4 technical replicates. Bar charts in e–g
represent mean ECAR ± s.e.m. For a–d *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. nsd, no significant difference. Statistical analysis, two-sided
Student’s t-test.
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Discussion
Overall, our data identify in vivo and in vitro evidence by which
CAFs regulate malignant cell metabolism. We show that reduced
FAK expression levels in FSP-1-positive subpopulation of CAFs
are sufficient to induce alterations in signalling and increase
tumour growth by enhancing discrete metabolic pathways in
cancer cells of the same oncogenic profile.
Our findings indicate that CAF-FAK expression regulates the
expression of chemokines Ccl6 and Ccl12, which through
malignant cell Ccr1/Ccr2 activity and PKA activation can control
cancer cell metabolism. The data establish a concept in CAF-
FAK-regulated and chemokine-mediated control of cancer
metabolism with relevance to human breast cancers with low
stromal FAK expression, and identify potential novel actionable
targets for anticancer therapy. Although growth factors have been
the focus of extracellular stimuli that initiate signal transduction,
induce entry into cell cycle and reprogramme the metabolism to
fulfil the biosynthetic needs of cell growth and division3, our
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study demonstrate that chemokines can also play similar roles
to support cancer cells and notably enhance malignant cell
metabolism.
Our major focus has been on the control of cancer cell Ccr1 and
Ccr2 in CAF-FAK regulation of malignant cell metabolism as we
detected the most significant increases in their ligands, Ccl6 and
Ccl12, respectively. However, additional CC chemokines including
Ccl7, Ccl8 and Ccl11, which can bind to other chemokine
receptors, are also upregulated in FAK-depleted CAFs. Consider-
ing that their associated receptors all belong to the same family of
GPCRs, it is plausible that additional chemokine–receptor inter-
actions contribute to the changes in the signalling and metabolic
networks that we have observed. Moreover, GPCR coupling
diversity can lead to distinct functional outcomes as different
receptors can selectively couple to multiple subtypes of G proteins,
exhibit differential engagement of various kinases and recruit
diverse conformational ensembles of beta-arrestins57. Receptor
heterodimerisation and the relative abundance of different che-
mokines would also very likely contribute to diversity in biased
signalling in this context. It is also plausible that activation of these
major signalling pathways alter the secretome of cancer cells in
FAK-depleted environment leading to additional changes in
autocrine signalling. Our data point towards activation of putative
signalling pathways downstream of chemokine receptors. Most of
these pathways can directly be regulated by PKA in addition to
PKA- and G protein-independent mechanisms and contribute to
distinct metabolic alterations in cancer cells within a FAK-
depleted stromal microenvironment.
Previous reports show that FAK regulation of cytokine pro-
duction is cell type-dependent and also influenced by the
experimental conditions9,13–15. Reconciling the different effects of
FAK loss in different cell types in a whole organism likely reflects
a combination of differences in cell functions, intrinsic molecular
profiles and local environmental stimuli in combination with
different effects on cytokine production. Our data indicate that
loss of FAK in CAFs from FSPCre−;FAKfl/fl mice increases Ccl6,
Ccl11, Ccl12 and pentraxin-3 expression with an enhancement in
malignant cell glycolysis and tumour growth. This control of
chemokine production aligns with work where Col1a-Cre driven
loss of FAK expression in activated fibroblasts from a hyper-
trophic scar formation model increases Ccl2 expression13. Con-
versely, although loss of FAK in endothelial cells of established
tumours had no effect on tumour blood vessel density, DNA-
damaging agent treatment of FAK-null endothelial cells induced
lower amounts of multiple interleukins, thus enhancing malig-
nant cell chemosensitivity and reducing tumour growth9. Future
investigations will determine the common and distinct molecular
mechanisms by which FAK controls cytokine production in dif-
ferent stromal cell types.
FAK has both kinase and scaffold functions and although
FAK-kinase inhibitors have shown promise in preclinical
studies14,15 the outcome of FAK inhibition in initial phase II
COMMAND-A trial clinical trial or phase II trial using the
combination of FAK inhibitor (GSK2256098) with Trametinib
have not been as encouraging as hoped for58,59. Further clinical
trials using FAK-inhibitors and combination with other therapies,
including immunotherapies, are predicted to be more promising
and will determine the full utility of FAK inhibitors across mul-
tiple cancer types15. Since FAK has both kinase and non-kinase
functions, it is fair to say that the effect of reduced FAK
expression levels and FAK kinase inhibition may not be identical.
The balance between signalling alterations due to direct effects of
FAK inhibition in cancer cells and stromal fibroblasts could
potentially be important to determine the overall treatment
outcome.
Our study points towards CAF-mediated mechanisms leading
to reduced overall survival in breast and pancreatic cancer
patients with low stromal FAK expression and highlight possible
metabolic/signalling pathways that could be targeted in these
patients.
Methods
Generation of mice. Female FAK floxed mice (C57/BL6) were bred with FSP-1 Cre
male mice (C57/BL6, originally developed by Prof Gustavo Leone, Cleveland Ohio,
USA)21,60,61 to generate FSP-Cre−;FAKfl/fl and FSP-Cre+;FAKfl/fl mice. MMTV-
PyMT+;FSP-Cre+;FAKfl/fl were also generated by crossing MMTV-PyMT+ mice
with FSP-Cre+;FAKfl/fl mice.
In our study, we used the FSP-1-Cre mice developed by Gustavo Leone,
Cleveland Ohio, USA. These FSP-Cre+ mice display Cre activity specific in a
subpopulation of activated fibroblasts and CAFs. FAK expression levels were not
affected in epithelial cells and macrophages isolated from MMTV-PyMT+;FSP-Cre
+;FAKfl/fl derived tumours indicating no effect in these cell types (Please see
Extended Fig. 2d, f, g).
To clarify, we have not used FSP-Cre mice from JaxLabs in this study.
Although, JaxLabs also sell an FSP-Cre mouse line, these mice show poor specificity
to fibroblasts or CAFs, and have also been shown to induce deletion of target genes
in other cell types including epithelial cells and macrophages. The reason for the
differences in the FSP-Cre+ transgenic from JaxLab and Leone’s laboratory are
likely to be related to the fact that they were generated independently by transgene
insertion of different sequences of the FSP promoter regions.
For animals bred in-house, health screens (quarterly) were conducted in
accordance with FELASA guidelines for health monitoring of rodent colonies, to
confirm their free status of known pathogens in accordance with FELASA screens.
No clinical signs were detected. Animals were housed in groups of 4–6 mice
per individually ventilated cage in a 12 h light dark cycle (06:30–18:30 light;
18:30–06:30 dark), with controlled room temperature (21 ± 1 °C) and relative
Fig. 4 Low stromal FAK expression enhance metabolic pathways in malignant cells. a Phosphoproteomics analysis defines a significant enrichment of
several metabolic processes in mouse malignant cells exposed to CM from FAK-depleted CAFs compared with malignant cells exposed to WT-CAF CM.
b Table: the expression levels of several glycolysis enzymes are significantly upregulated (red) in proteomics analysis of mouse malignant cells exposed to
FAK-depleted CAF CM when compared with malignant cells exposed to WT-CAF CM. Box and whisker plots indicate significant transcriptional upregulation
of genes encoding glycolytic enzymes in the cancer cells of patient tumours with low stromal FAK compared with high stromal FAK. c Box and whisker plots,
elevated IDH, SDH and FH gene transcription in the epithelial compartment of patient tumours with low stromal FAK. Table: Mouse proteomics data
indicate a significant enrichment of IDH peptides in mouse malignant cells exposed to CM from FAK-depleted CAFs compared with malignant cells
exposed to WT-CAF CM. d Box and Whisker plots show elevated transcription of genes encoding enzymes of fatty acid metabolism in the epithelial gene set
of human breast cancer with low stromal FAK. Table: HADHA upregulation at the protein level in mouse malignant cells exposed to CM from FAK-depleted
CAFs. For all human data, n= 39 breast cancer patients with high stromal FAK, n= 9 breast cancer patients with low stromal FAK (from Finak et al.
dataset); for all mouse data n= 3 mouse malignant cell preparations exposed to WT-CAF CM and n= 3 mouse malignant cell preparations exposed to
FAK-depleted CAF CM. Box and whisker plots—box denotes the interquartile range (IQR, Q1 25th percentile—Q3 75th percentile), and whisker denotes
the maximum (Q3+ 1.5IQR) and minimum (Q1–1.5IQR). The median value is shown by the horizontal line within the box. *P < 0.05,**P < 0.01,***P < 0.001,
****P < 0.0001. nsd, no significant difference. Statistical analysis, two-sided Student’s t-test. e The transcriptome of cancer cells in breast cancer patients
with low vs high stromal FAK were compared using Reactome database. GSEA shows that many pathways regulating cellular metabolism are upregulated
in the cancer cells in patient tumours with low stromal FAK expression levels. Disc sizes reflect the number of differentially expressed hits from each
pathway. Colour bar indicates FDR q-value significance.
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humidity (40–60%). The cages contained 1–1.5 cm layer of animal bedding, and
with environmental enrichment including cardboard Box-tunnel and crinkled
paper nesting material. Animals had access to food and water ad libitum.
Cell culture. E0771 murine breast cancer cells (derived from C57/BL6) were
obtained from Prof Anne Ridley (Bristol University, UK) and grown in RPMI
medium supplemented with 10% FBS and 1% penicillin streptomycin. KrasLSL.
G12D/+; p53R172H/+;PdxCre+ (KPC)-derived TB32048 murine pancreatic cancer
cell line (derived from C57/BL6) was obtained from Prof David Tuveson (Cold
Spring Harbour, USA) and cultured in DMEM supplemented with 10% FBS and
1% penicillin streptomycin. Primary mouse lung fibroblasts and MMTV-derived
CAFs were cultured in DMEM supplemented with 10% FBS, 1% Insulin-
Transferrin-Selenium (ITS) supplement and 1% penicillin streptomycin. MMTV-
derived primary tumour cells were cultured in Advanced DMEM/F12 supple-
mented with 2% FBS, 1% penicillin streptomycin, GlutaMAX, Insulin and EGF
(20 µg/µL) and on collagen-coated dishes.
Isolation of CAFs and cancer cells from MMTV-PyMT tumours. CAFs were
isolated from MMTV+;FSP-Cre−;FAKfl/fl and MMTV+;FSP-Cre+;FAKfl/fl mice as
described previously62. Tumours were cut into small pieces and digested for 1 h at
37 °C in 5 mL collagenase/dispase (1 mg/mL; Sigma). After filtering the undigested
tissue, the solution was centrifuged (3000 g, 5 min) and the final pellet was
resuspended in DMEM high glucose, 10% FBS, 1% ITS and seeded on a 6 cm dish.
After 30 min, fibroblasts are adhered and non-adherent tumour cells were replated
and cultured as described above. Adherent fibroblasts were used after 1–3 passages.
Intrapancreatic injection. Eight- to 10-week-old male mice were anaesthetised
with isoflurane. The abdominal skin and muscle were incised just off the midline
and directly above the pancreas to allow visualisation of the pancreatic lobes; the
pancreas was gently retracted and positioned to allow for a direct injection of 10 µL
of 1 × 103 TB32048 cells in PBS-Matrigel (1:1) using a Hamilton syringe. The
pancreas was placed back within the abdominal cavity. Both the muscle and skin
layers were closed with 6-0 silk sutures (Ethicon). Mice were kept on a heat box
during the entire procedure.
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Mammary fat pad injection. Eight- to 10-week old female mice were anaesthetised
with isoflurane. A vertical incision was made through the abdominal skin, but not
the peritoneum. The skin was pulled away from the peritoneum to expose the
fourth inguinal mammary gland and 4 × 105 E0771 tumour cells were injected
unilaterally in 20 µL of PBS-matrigel using a 28-gauge needle.
Immunohistochemistry and immunofluorescence for endomucin and quanti-
fication of blood vessel density. Tissues were fixed in formalin for 24 h and
transferred to 70% ethanol. Tissues were paraffin embedded, sectioned, dewaxed,
and antigen retrieval performed by boiling in 10 mM citrate buffer pH 6.0. Sections
were washed three times in PBS, blocked in 5% normal goat serum for 1 h, and
incubated with primary antibody rat monoclonal endomucin (1:100 dilution; Santa
Cruz, #sc-65495) overnight at 4 °C. Sections were then washed and incubated for
45 min with secondary fluorophore (1:100; AlexaFluor 488 goat anti-rabbit IgG;
LifeTechnologies, #A11008) for endomucin staining and finally mounted with
Prolong antifade with 4′,6-diamidino-2-phenylindole (DAPI; Molecular Probes).
Images were taken with an Axioplan Zeiss microscope. To quantify the tumour
blood vessel density, the number of endomucin-positive blood vessels present
across the entire area of each midline tumour section from size and age-matched
tumours was counted and divided by the area of the section.
Picrosirius Red staining. For collagen staining, sections were dewaxed and
hydrated before staining in Picrosirius Red solution (DirectRed 80; Sigma-Aldrich,
#365548) for 1 h. The sections were washed twice in acidified water and then
mounted for microscopy. Positive fraction of area (%) of red staining of the entire
section was quantified after setting up a threshold using ImageJ.
Immunohistochemistry using the Ventana automated system for
Ki67 staining. IHC was performed using the fully automated Ventana Discovery
XT (Roche Diagnostics, Rotkreuz, Switzerland). All steps were performed on the
machine with Ventana solutions. Briefly, dewaxed and rehydrated paraffin sections
were pretreated with heat using mild condition (20 min) CC1 solution. Sections
were incubated with the primary antibody (1:100; Abcam, #ab16667) for 1 h at
37 °C. After incubation with OmniMap-anti-rabbit HRP (1:100), chromogenic
revelation was performed with DAB (Roche). Sections were counterstained with
haematoxylin.
In situ hybridisation, RNA-ISH. In situ hybridisation for Fsp1 and Fak expression
was performed on 5 μm FFPE sections using the RNAscope 2.5 HD Duplex
(#322436) assay according to the manufacturers’ instructions (Advanced Cell
Diagnostics, Newark, CA). RNAscope probes used were Mm-S100a4 (Fsp1,
#412971), Hs-CD274 (FAK, #600861), Mm-Ccl6 (#510851), Mm-Ccl12 (#437521),
Mm-Ppib (positive control probe, #313911) and 3-plex Negative Control Probe
(#320871). Stained slides were stored at 4 °C before imaging on a Zeiss
brightfield microscope.
Pimonidazole detection of hypoxia. One hour prior to sacrifice, tumour-bearing
mice were injected with 60 mg/kg pimonidazole hydrochloride (Hypoxyprobe™-1
HPI, Inc.) diluted in ddH2O to a final concentration of 10 mg/mL) intravenously
via the tail vein. Tumours were snap frozen immediately after cervical dislocation.
Five-micrometre cryosections were thawed, rehydrated and fixed for 10 min in
−20 °C acetone. Sections were incubated with 1:50 anti-pimonidazole overnight at
4 °C. Sections were then washed and mounted with ProLong Gold™ with Antifade
(Invitrogen). Images were taken with an Axioplan Zeiss microscope.
Vascular perfusion. Vascular perfusion was visualised by injecting mice via the
tail vein with 20 µg of PE-conjugated mouse monoclonal anti-PE-PECAM (Bio-
legend, #102408) 10 min prior to sacrifice. Tumours were snap frozen, sectioned
and stained for endomucin as above. The percentage of double-positive blood
vessels was presented as an indication of blood vessel perfusion.
Western blotting. Cells were grown to 70–80% confluency. RIPA buffer was used
for lysis for all experiments apart from those for PI3K inhibition where high SDS
buffer was used instead. Five to 10 μg protein was run on 15% polyacrylamide gel
for FSP-1 and 8–10% polyacrylamide gel for others and then transferred to
nitrocellulose membranes. The membranes were blocked for 1 h in 5% milk in
phosphate-buffered saline with 0.1% Tween-20 (PBS-T), followed by an overnight
incubation of primary antibody diluted 1:1000 in 5 mL of 5% BSA in PBS-T at 4 °C.
The blots were then washed three times with 10 mL of PBS-T and incubated with
the relevant horseradish peroxidase (HRP)-conjugated secondary antibody diluted
1:2500 in 5% milk in PBS-T for 1 h at room temperature. After further washes in
PBS-T, bands were detected by chemiluminescence. HSC70 or GAPDH were used
as loading controls. The following antibodies were used: HSC70 (1:5000 dilution,
Mouse monoclonal; Santa Cruz, #sc7298), GAPDH (1:5000 dilution, Mouse
monoclonal, clone 6C5; Millipore, #MAB374) smooth muscle actin (1:1000 dilu-
tion, Mouse monoclonal, Clone 1A4; DAKO, #M0851), FAK (1:1000 dilution,
Mouse monoclonal, Clone 4.47; Millipore, #05-537), FSP-1 (1:500 dilution, Rabbit
polyclonal; Millipore, #07-2274), PDGFR-β (1;1000 dilution, Rabbit monoclonal,
Clone 28E1; Cell Signaling, #3169), E-cadherin (1:1000 dilution, Rabbit mono-
clonal, Clone 24E10; Cell Signaling, #3195), Endomucin (1:1000 dilution, Rat
monoclonal; Santa Cruz, #sc65495), Pyk2 (1:1000 dilution, Mouse monoclonal;
Cell Signaling, clone 5E2, #3480), phospho-AKT (Ser473) (1:1000 dilution, Rabbit
monoclonal, 193H12; Cell Signaling, #4058).
Phenotypic analysis of tumours by flow cytometry. Tumours were minced and
incubated at 37 °C for 20 min in an enzymatic cocktail containing DNase (0.5 mg/
mL; Sigma). Collagenase type V (2 mg/mL; Sigma) in HBSS (Sigma) was used to
make a single-cell suspension for pancreatic tumours. For breast tumours, col-
lagenase/dispase (1 mg/mL, Sigma) in PBS was used to make a single-cell
suspension.
Cells were passed through a 70 μM filter (BD Biosciences), washed in PBS
supplemented with 2% foetal bovine serum and 2mM EDTA, counted and used
immediately for flow cytometry. Before cells were stained with specific antibodies,
nonspecific binding sites were blocked with Fcγ R III/II TruStain fcX (93,
Biolegend). Staining was performed in PBS supplemented with 2% foetal bovine
serum and 2 mM EDTA.
The following fluorochrome-conjugated antibodies were used: anti-CD45
(1:100, 30-F11, #103149), anti-CD3ε (1:50, 145-2C11, #100320), anti-CD4 APC
(1:200, RM4-4, #116014), anti-CD8APC/PE (1:200, 53-6.7, #100712, #100708),
anti-CD69 (1:100, H1.2F3, #104506), anti-CD44 (1:100, IM7, #103049), anti-
CD62L (1:100, MEL-14, #104438), anti-CD19PerCP (1:200, 6D5, #115532), anti-
CD11b (1:100, M1/70, #101259), anti-F4/80 PE (1:50, BM8, #123110) all from
Biolegend; anti-PD1 (1:100, RMP1-30, #48-9981-80), anti-Gr1 (1:200, RB6-8C5,
#56-5931-82) and anti-Ly6C (1:100, HK1.4, 48-5932-82) all from eBioscience.
Fixable viability dye (1:500, FVD, #65-0866-14) (eBioscience) was used to
discriminate between live and dead cells. Acquisition and analyses were performed
on a BD LSRII system using BD FACSDIVA software (BD Biosciences). The
percentage of cells were analysed using FlowJo software (version 10.0.8 tree Star).
Dead cells were excluded from the analysis on the basis of FVD and SSC gating.
Cell doublets were excluded from the analysis by gating for FSC area versus FSC
width. CD45+ cells were used to include leucocytes only in the data analysis. For
Gating strategy please see Supplementary Fig. 8.
Fig. 5 CAF-FAK depletion increases expression Ccl6 and Ccl12. a Primary MMTV-derived malignant cells were incubated with the conditioned medium
(CM) from primary WT and FAK-depleted CAFs for 48 h. CM from FAK-depleted CAFs enhanced the glycolysis, glycolytic capacity and glycolytic reserve
of malignant cells significantly; n= 4 independent experiments; n= 5 WT CM incubated malignant cells and 3 FAK-depleted CM incubated malignant cells
from the representative run. Bar chart shows mean ECAR ± s.e.m. b Exposure of malignant cells to CM from FAK-depleted CAFs only for 2 h also increased
glycolytic capacity and reserve. Upon boiling the CM for 10 min at 100 °C to inactivate growth factors and cytokines, these metabolic alterations did not
persist suggesting a predominantly non-metabolite based communication between CAFs and malignant cells in the regulation of malignant cell
metabolism; n= 4 independent experiments, 5 technical repeats for each genotype from the representative run. Bar chart shows mean ECAR ± s.e.m.
c Ontology enrichment analysis of quantitative proteomics data from FAK-depleted CAFs displayed PI3K and cytokine-mediated signalling cascades as the
most enriched pathways relative to control WT-CAFs. d Proteome profiler arrays identified Ccl6, Ccl11, Ccl12 and Pentraxin-3 as the most upregulated
cytokines in primary FAK-depleted CAFs compared with controls; n= 4 technical repeats from two independent cell preparations. Bar chart shows mean
densitometry (AU) ± s.e.m. e qRT-PCR reveals enhanced Ccl6, Ccl12 transcription in FAK-depleted CAF cells; n= 2 WT and 4 FAK-depleted cell preps. Bar
chart represents mean mRNA expression (fold change) ± s.e.m. f RNAscope images of Fsp-1 and Ccl6 or Ccl12 in tumour sections from MMTV+;FSP-Cre−;
FAKfl/fl and MMTV+;FSP-Cre+;FAKfl/fl mice. Note the increased number of cytokine transcripts (purple) in FSP-1-positive cells (green) in MMTV+;
FSP-Cre+; FAKfl/fl mice. Scale bars in f 50 μm. g CCL23, human orthologue of mouse Ccl6, is inversely correlated in human breast cancer patients with
stromal FAK expression. *P < 0.05,**P < 0.01,***P < 0.001,****P < 0.0001. nsd, no significant difference. Statistical analysis, a–e two-sided Student’s test.
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Isolation and culture of bone marrow-derived macrophages. Tibias and femurs
were harvested from mice. Under sterile conditions, the ends of the bone were held
with sterile forceps and a 27G needle (BD Biosciences) syringe containing 10mL of
PBS was used to flush cells from the bone marrow. Single-cell suspensions were washed
with PBS and resuspended in 5mL of red blood cell lysis buffer (BD Biosciences).
Single-cell suspension was passed through a 70-μm cell strainer (BD Falcon)
and counted. After centrifugation, cells were resuspended in complete medium and
plated in a 150 mm bacterial Petri dish (Thermo Fisher Scientific) containing 20
ng/mL of recombinant CSF-1 (BD Biosciences) and incubated for 7 days at 37 °C in
a 5 % v/v CO2 atmosphere.
Magnetic resonance imaging. To monitor tumour growth, MR imaging using a
Bruker ICON™ 1T MRI system (Bruker, Ettlingen, Germany) was performed on
mice that had been subjected to orthotopic pancreas surgery. Mice were anaes-
thetised with 1.3–3% isoflurane at 1 L/min and maintained at 37 °C throughout the
f g Kinase substrate enrichment analysis
most significantly enriched substrates in mouse
malignant cells exposed to FAK-null CAFs CM
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imaging procedure. Using a 30 mm i.d., ×50 mm mouse body coil, T2-weighted
scans with respiratory gating were performed (acquisition software: ParaVision
Acquisition 5.1) using the following acquisition protocol: pulse sequence (RARE),
echo time (84.00 ms), repetition time (3149.139 ms), averages (4), rare factor (8),
number of coronal slices (13), slice thickness (0.850 mm), slice gap (0.250 mm),
matrix size (110 × 110), field of view (30 × 30mm), resolution (0.273 × 0.273 mm)
and imaging time less than 3 min. Images were analysed using VivoQuant 3.0
analysis software (inviCRO LLC, Boston, MA). For quantitative analysis, total
tumour volume was calculated by adding together the volumes (mm3) per slice of
tumour for each individual mouse.
18F-FDG PET/CT Imaging. All animals were fasted overnight for at least 12 h prior
to 18F-FDG PET/CT scans. Blood glucose was measured and the animals weighed
prior to administration of 10–15MBq of 18F-FDG in a volume of 200 µL via the tail
vein. Animals were maintained under isoflurane anaesthesia (1.5% at 1 L/min) at
37 °C for a 60 min uptake period after which an attenuation CT scan was per-
formed (10 min duration) followed by PET scanning under the same temperature
and anaesthesia levels. A Siemens Inveon PET/CT scanner (Siemens Preclinical
Solutions Knoxville, TN) was used in combination with Inveon Acquisition
Workplace software (version 1.5 Siemens Medical Solutions MI) for all imaging
procedures. PET data acquired using a 350–650 keV energy window were recon-
structed to a 128 × 128 × 159 matrix with a voxel size of 0.776 mm × 0.776 mm ×
0.796 mm using the 3D-ordered subsets expectation maximisation (OSEM3D)
reconstruction algorithm with CT attenuation and scatter correction applied (2
OSEM3D iterations, 18 MAP Iterations). MicroCT scans were acquired using the
factory set attenuation CT protocol with the following parameters: 3 bed positions
(to match the PET field of view), 120 rotation steps over 220°, continuous rotation,
80 kVp tube voltage, 500 μA tube current, 200 ms exposure and a binning setting of
4 yielding an effective pixel size of 108.07 µm. The CT images were reconstructed
using the factory set attenuation CT reconstruction protocol into a 384 × 384 × 604
matrix with an isotropic voxel size of 0.216 mm × 0.216 mm × 0.216 mm and
Hounsfield calibration was applied. For quantitative assessment, images were
analysed using VivoQuant 3.0 analysis software (inviCRO LLC, Boston, MA). PET
and CT images were co-registered and volumes of interest (VOIs) were generated
to match breast tumour volume. Uptake in the tumours was calculated as SUVmax.
Infusions of 13C-labelled nutrients and dissection of tumours. For isotopomer
analysis of glucose metabolism, tumour-bearing mice were injected with a bolus
dose of 20 mg [U-13C6]-glucose (Cambridge Isotope Laboratories) via tail vein.
Mice were sacrificed 15 min after the last injection. Tumours were dissected
rapidly, snap frozen and stored at −80 °C.
Sample preparation and LC-MS analysis. Snap-frozen tissue specimens were cut
and weighed into Precellys tubes prefilled with ceramic beads (Stretton Scientific
Ltd, Derbyshire, UK). An exact volume of extraction solution (30% acetonitrile,
50% methanol and 20% water) was added to obtain 40 mg specimen per mL of
extraction solution. Tissue samples were lysed using a Precellys 24 homogeniser
(Stretton Scientific Ltd, Derbyshire, UK). The suspension was mixed and incubated
for 15 min at 4 °C in a Thermomixer (Eppendorf, Germany), followed by cen-
trifugation (16,000 g, 15 min at 4 °C). The supernatant was collected and trans-
ferred into autosampler glass vials, which were stored at −80 °C until further
analysis.
Samples were randomised in order to avoid bias due to machine drift and
processed blindly. LC-MS analysis was performed using a QExactive Orbitrap mass
spectrometer coupled to a Dionex U3000 UHPLC system (Thermo). The liquid
chromatography system was fitted with a Sequant ZIC-pHILIC column (150 mm ×
2.1 mm) and guard column (20 mm × 2.1 mm) from Merck Millipore (Germany)
and temperature maintained at 45 °C. The mobile phase was composed of 20 mM
ammonium carbonate and 0.1% ammonium hydroxide in water (solvent A), and
acetonitrile (solvent B). The flow rate was set at 200 µL/min with the gradient
described previously63. To expand on the range of metabolites covered in the
analysis, the sample extracts were then run on a ZIC-HILIC column (150 mm × 4.6
mm) fitted with a guard column (20 mm × 2.1 mm) (both Merck Millipore,
Germany). The aqueous mobile phase solvent used was 0.1% formic acid in water
(solvent A) and the organic mobile phase was 0.1% formic acid in acetonitrile
(solvent B). The flow rate was set at 300 μL/min and the column oven set to 30 °C.
The mobile phase gradient was described previously63. The mass spectrometer was
operated in full MS and polarity switching mode. The acquired spectra were
analysed using XCalibur Qual Browser and XCalibur Quan Browser software
(Thermo Scientific).
Cytokine arrays. Wild type and FAK-depleted CAFs were grown in normal
DMEM media supplemented with 10% FBS. Whole-cell lysates were extracted
when cells were 70–80% confluent. Mouse XL cytokine arrays (Proteome Profiler
ARY028, R&D Systems) were performed according to the manufacturer’s
Fig. 6 CCR1/2 or PKA inhibition rescues the enhanced metabolism in malignant cells. a Treatment of epithelial cells isolated from MMTV+;FSP-Cre−;
FAKfl/fl mice with recombinant Ccl6 and Ccl12 for 5 h increases glycolytic capacity in extracellular flux analysis; n= 8 non-treated and 10 recombinant Ccl6
and Ccl12 epithelial cell treated technical replicates. b Extracellular flux analysis of malignant cells exposed to WT-CAF CM with or without CCR1i/CCR2i
for 48 h shows that these inhibitors have no apparent effect on glycolysis, glycolytic capacity or glycolytic reserve; n= 8 biological repeats-CCR1i/CCR2i,
n= 9 biological repeats+ CCR1i/CCR2i. c Extracellular flux analysis of epithelial cells isolated from MMTV+;FSP-Cre;FAKfl/fl mice treated with CM from
either WT or FAK-depleted CAFs in the absence or presence of the dual CCR1i/CCR2i shows that dual inhibition of CCR1 and CCR2 is sufficient to rescue
the metabolic alterations in cancer cells treated with FAK-depleted CAF CM; n= 3 independent experiments; n= 12 WT-CAF-CM—CCR1i/CCR2i, n= 12
FAK-depleted CAF-CM—CCR1i/CCR2i, n= 10 FAK-depleted CAF-CM+CCR1i/CCR2i. d Effect of CCR1/CCR2- siRNA depletion on breast cancer cell
E0771 metabolism. Without exposure to CAF-CM, under normal culture conditions, CCR1/CCR2 depletion in E0771 cells (n= 10 glycolytic capacity; n= 12
glycolytic reserve) does not affect glycolytic capacity or glycolytic reserve compared with no-treatment (NT) (n= 12), mock (n= 12) or scrambled (scr)
(n= 12) negative controls. CCR1/CCR2 depletion in E0771 cells had no significant effect on glycolytic capacity (n= 10) or glycolytic reserve (n= 10) after
exposure to WT-CAF CM, but significantly reduced the enhanced glycolytic capacity (n= 12) and glycolytic reserve (n= 12) after exposure to FAK-
depleted CAF CM. Statistics, two-way ANOVA. Bar charts in a–d show mean ECAR ± s.e.m. e E0771 tumour volumes, at day 28 post tumour cell
inoculation in FSP-Cre−;FAKfl/fl and FSP-Cre+;FAKfl/fl mice. Cohorts: Untreated FSP-Cre−;FAKfl/fl mice (n= 22 mice); untreated FSP-Cre+;FAKfl/fl mice (n=
26 mice); vehicle-treated FSP-Cre−;FAKfl/fl mice (n= 15 mice); CCR1i/CCR2i-treated FSP-Cre−;FAKfl/fl mice (n= 10 mice) and CCR1i/CCR2i-treated FSP-
Cre+;FAKfl/fl mice (n= 12 mice). Bar chart shows mean tumour volume (mm3) ± s.e.m. f FSP-Cre+; FAKfl/fl mice treated with CCR1i/CCR2i and vehicle-
treated FSP-Cre−; FAKfl/fl mice, both bearing early-stage, size-matched E0771 tumours, were continuously infused with [U-13C6] glucose and LC-MS
analysis of whole tumours was performed. Inhibition of CCR1/CCR2 reduced the levels of isotopologues of glucose, lactate, succinate, fumarate, malate,
aspartate and glutamate from tumours grown in FSP-Cre+;FAKfl/fl mice. Bar charts show mean % of the indicated isotopologue pool over the total
metabolite pool ± s.e.m. n= 4 FSP-Cre−; FAKfl/fl and 5 FSP-Cre+; FAKfl/fl tumours. g Kinase substrate enrichment analysis (KSEA) of phosphoproteomics
data showed a significant enrichment of PKD1, p38δ, p90RSK, PKACA, ROCK2, PAK4, DAPK3, DAPK1, p38α and MLCK substrates in cancer cells exposed
to CM from FAK-depleted CAFs; n= 3 independent cell lysates for each genotype, two-sided Student’s t-test. h Epithelial transcript levels of the genes
encoding PRKAR1A, KSR, RAP1A, MAP2K3, RAC1, CTNNB1 and LEF1 are significantly enriched in human breast cancer gene set of cancers with low stromal
FAK levels; Box and whisker plots show log-ration mRNA expression and include maximum and minimun data points, median value and 75th and 25th
quartile. n= 39 patients with high stromal FAK and 9 patients with low stromal FAK, Student’s t-test. i Seahorse analysis of epithelial cells exposed to CM
fromWT-CAFs and FAK-depleted CAFs plus the PKA inhibitor, KT 5720 (+) or vehicle alone (veh) for 3 h show that treatment with PKA inhibitor reduces
the enhanced glycolytic capacity and glycolytic reserve in primary tumour cells exposed to CM from FAK-depleted CAFs that of tumour cells exposed to
WT-CAF CM. Bar chart shows mean ECAR ± s.e.m. n= 2 cell preparations, scatter dots represent n= 11 WT-CAF CM- veh, n= 5 FAK-depleted CAF-CM-
veh, n= 6 FAK-depleted CAF-CM+ inhibitor technical repeats from one representative run. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. nsd, no
significant difference. Statistical analysis, two-sided Student’s t-test unless otherwise stated.
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instructions using 100 μg of lysates per membrane. Pixel analysis was used for
quantification with ImageJ software.
Ccl6 and Ccl12 stimulation of primary MMTV-derived tumour cells. Tumour
cells were starved for 12 h in serum-free culture medium followed by 5-h treatment
with mouse recombinant Ccl6 (200 ng/mL; Peprotech, #250-06) and Ccl12 (5 ng/
mL; BioLegend, #587904) before extracellular flux analysis. Concentration used are
within physiological local tissue cytokine expression level ranges.
Ccr1/Ccr2 siRNA of E0771 cells. E0771 cells were seeded either in a six-well plate
(100,000 cells/well; for qRT-PCR) or into a Seahorse plate (30,000 cells/well), the
day before transfection to achieve 60–70% confluency. For transfection of Ccr1 and
Ccr2 siRNA (ON-TARGETplus from Horizon Discovery—12768, 12772), jet-
PRIME transfection reagent (Polyplus, #114-07) was used according to the man-
ufacturer’s instructions. On-TARGETplus non-targeting pool (Horizon Discovery,
#D-001810-10) was used as a negative control siRNA. Cells were incubated in their
normal culture medium before and during transfection for 24 h. Ccr1, Ccr2 and
non-targeting control siRNA were all used at 25 nM concentration. After 24 h, the
medium was removed and replaced with either FAK-depleted CAF conditioned
medium or FAK-WT-CAF conditioned medium for 4 h, or maintained in normal
culture medium as a control. After 4 h, extracellular flux analysis experiments were
performed. For the six-well plate, at the end of the 4 h incubation with conditioned
medium, cells were pelleted and stored at −80 °C prior to RNA extraction.
Quantitation of Ccr1 and Ccr2 levels: RNA was extracted from E0771 cells
transfected with Ccr1 and Ccr2 siRNA using the RNA isolation kit according to the
manufacturer’s instructions (RNeasy mini kit, Qiagen, cat no. 74106) and RNA
concentrations were quantified using the Nanodrop spectrophotometer (Thermo
Fisher Scientific). In all, 1 μg/μL RNA was converted to cDNA using the High
Capacity cDNA reverse transcription kit (Thermo Fisher Scientific, #4368814).
Ccr1, Ccr2 and Actin primers and probes for qRT-PCR Taqman reactions were
obtained from Applied Biosystems. cDNA samples were run in triplicate for each
treatment. Gene expression levels of Ccr1 and Ccr2 were analysed using the Ste-
pOne Real Time PCR machine and software (Applied Biosystems).
Quantitative real-time PCR. Primary MMTV-derived CAFs were lysed in RLT
buffer (Qiagen). Total mRNA was isolated using the RNeasy Mini kit (Qiagen).
Quality control and concentration of samples was carried out using a Nanodrop
ND-10000 spectrophotometer. RNA was reverse transcribed using High Capacity
cDNA Reverse Transcription kit (Applied Biosystems) according to the manu-
facturer instructions. Real-time PCR was performed in a StepOne Plus thermo-
cycler (Applied Biosystems) using TaqMan Master mix and primers custom-made
that were specific to mouse Ccl6 (Mm01302419), mouse Ccl12 (Mm01617100),
mouse Ccl7 (Mm00443113), mouse Ccl8 (Mm01297183), mouse Ccr2
(Mm01216173) and Gapdh (4352339E) all from Applied Biosystems. The data
were normalised to Gapdh endogenous control to compensate for experimental
variations. Fold changes were calculated using the comparative CT (cycle thresh-
old) method.
Seahorse XFe Extracellular Flux Analyser experiments. For the assay, cells were
plated in XFe96 Cell Culture Microplates (Agilent Technologies) at a cellular
density of 30,000 cells/well as follows: EpCAM+ sorted malignant cells from fresh
MMTV tumours were seeded on the day of the assay in previously-coated plates;
E0771 cells with mock transfection, scr siRNA or Ccr1/Ccr2 siRNA transfection
(see Ccr1/Ccr2 siRNA of E0771 cells); primary malignant cells or CAFs, that were
in culture, were seeded 24 h prior to the assay. For oxygen consumption rate (OCR)
determination, cells were incubated in base assay medium (Agilent Technologies)
supplemented with 2 mM glutamine, 10 mM glucose and 1 mM pyruvate for 1 h,
prior to the measurements using the XF Cell Mito Stress Kit (Agilent Technolo-
gies). Concentrations of oligomycin, FCCP, antimycin and rotenone were adjusted
for each cell type. For glycolytic metabolism measurements, cells were incubated in
basal media (Agilent Technologies) supplemented with 2 mM glutamine and 1 mM
pyruvate for 1 h prior to injections using the Glycolysis Stress Test Kit (Agilent
Technologies). Experiments were run in a XF96e analyser (Agilent Technologies),
and raw data were normalised to protein content calculated by Bradford method.
Where appropriate, conditioned medium (CM) from WT and FAK-depleted CAFs
were collected over a 48 h time period in normal culture medium. CM was either
used fresh or boiled for 10 min to inactivate proteinaceous factors before applying
to malignant cells for 2 or 48 h before flux analysis was performed.
Fibroblast activation in vivo. Bleomycin A5 hydrochloride (#ab142406) was
purchased from AbcamBiochemicals. Mice were anaesthetised using isoflurane and
treated with 10 mg/kg (in saline) through intranasal instillation. Mice were culled
21 days after the treatment and fibroblasts were isolated.
Drug treatments followed by qRT-PCR and extracellular flux analysis. For
qRT-PCR, primary CAFs were treated with 1 µM PI3K inhibitor (GDC-0941;
Selleckchem, #S1065) for 24 h or 5 µM FAK inhibitor (PF-573,228; Tocris, #3239)
for 48 h. For seahorse experiments, cancer cells were exposed to conditioned
medium from CAFs with 10 µM PKA inhibitor (KT 5720; Tocris, #1288), 10 µM
PKC inhibitor (Go6983; Tocris, 2285/1#) for 3 h. Alternatively, cancer cells were
incubated in CAF CM with 1 µM CCR1i (Chemocentryx) and 1 µM CCR2i
(Chemocentryx) for 48 h.
In vivo treatment of orthotopic breast tumour-bearing mice with CCR1i/
CCR2i. CCR1i and CCR2i were discovered through structure–activity relationship
modification of screening hits and synthesised by the Medicinal Chemistry
Department at ChemoCentryx (Mountain View, CA) according to the procedures
described (Patent Application Numbers: WO 2014089495 and WO 2016187393)64.
HydroxylPropyl MethylCellulose (HPMC, The Dow Chemical Company, Midland,
MI, USA) was employed as the suspending agent in formulations for in vivo
experiments. HPMC was dissolved in USP Sterile Water (Mediatech, Inc., Mana-
ssas, VA, USA) and the placebo vehicle was 1% w/v HPMC. Drug formulations
were prepared by weighing the required amount of CCR1i and CCR2i into a
mortar, followed by slow addition of 1% w/v HPMC vehicle into the mortar with
continuous mixing with a pestle until a homogeneous suspension was produced.
The concentrations of CCR1i and CCR2i in the formulation were both 6 mg/mL
(30 mg/Kg dose and 5 mL/Kg dosing volume). The inhibition of chemotaxis was
assessed in WEHI-274 murine monocyte cell line64 that endogenously express
CCR1 and CCR2. Employing the WEHI-274 cell line, independently CCR1i and
CCR2i inhibited CCR1 and CCR2 mediated chemotaxis with IC50 of 20 nM,
respectively, in 100% mouse serum.
FSP-Cre+;FAKfl/fl mice were dosed by oral gavage with CCR1i and CCR2i once
daily (1% HPMC in water) both at 30 mg/kg. FSP-Cre−;FAKfl/fl mice were dosed
1% HPMC in water in parallel as the vehicle control. Dosing began on day 8 and
continued until day 20 for LC-MS or day 28 for tumour growth experiments.
Trough plasma levels were above the IC90 for each compound resulting in complete
CCR1 and CCR2 receptor engagement by CCR1i and CCR2i, respectively.
CCR1i and CCR2i specificity assays. The following describes each assay in the
following format: receptor: cell type/ligand/function tested. CCR1: THP-1 cells/
lymphotactin/cell migration; CCR2: peripheral blood mononuclear cells/MCP1/
Ca2+ flux; CCR3: transfected 293 cells/eotaxin/Ca2+ flux. CCR4: peripheral blood
T cells/MDC/Ca2+ flux; CCR5: transfected L1/2 cells/labelled MIP-1β/ligand
binding; CCR6: peripheral blood T cells/MIP-3α/Ca2+ flux; CCR7: peripheral
blood T cells/MIB-3β/Ca2+ flux; CCR8: transfected 293 cells/I309/Ca2+ flux;
CCR9: MOLT-4 cells/TECK/cell migration; CCR10: transfected 293 cells/CCL28/
Ca2+ flux; CXCR1: peripheral blood neutrophils/IL8/Ca2+ flux; CXCR2: per-
ipheral blood neutrophils/GRO-α/Ca2+ flux; CXCR3: peripheral blood lympho-
cytes/ITAC/Ca2+ flux; CXCR4: peripheral blood lymphocytes/SDF1α/Ca2+ flux;
CXCR5: transfected L1/2 cells/BCA-1/Ca2+ flux; CXCR6: peripheral blood lym-
phocytes/CXCL16/Ca2+ flux; C3aR: /peripheral blood neutrophils/complement
C3a/Ca2+ flux; C5aR/peripheral blood neutrophils/complement C5a/Ca2+ flux;
FPRL1: peripheral blood neutrophils/CCL23(aa22–137)/Ca2+ flux.
Gene expression data analysis and clinical inferences. Published datasets for
breast cancer16 and pancreatic cancer18 were used for the human cancer stroma
gene expression analysis. Gene expression profiling (GEP) data of tumour-
associated stroma derived from primary breast cancer samples (n= 53)16 were
extracted and used to inspect the association between FAK expression in stroma
and overall survival (OS). Of the three probes mapped to FAK/PTK2 gene, the two
probes (Agilent-012391 Whole Human Genome Oligo Microarray G4112A, plat-
form GPL1708, probe 1: Agilent feature number 4302; probe 2: Agilent feature
number 11888) with the most expression abundance were used for the following
analysis (Extended Fig. 1a). The high- and low-expression groups were determined
using the method described previously65. Briefly, each percentile of expression
between lower and upper quartiles was used in the Cox proportional hazards
(Coxph) regression analysis and the best performing threshold of percentile
associated with OS was determined. Survival modelling and Kaplan–Meier (KM)
analysis was undertaken using R “survival” package. OS was defined as time from
diagnosis to death or to the last follow-up date for survivors. We further assessed
the clinical association of FAK expression using the multivariate analysis,
accounting for age, tumour grade, ER status, tumour size, status of radiotherapy,
hormone-therapy and chemotherapy. Hazard ratio (HR) and 95% confidence
interval (CI), as well as associated P values at the best performing threshold, were
then derived. The KM analysis was also performed using the median cutoff (equal
number split), and the similar trend was observed to that using the best performing
threshold.
A primary pancreatic cancer dataset18 was also selected, with both GEP and
clinical data available (n= 102), for the clinical inference of FAK expression.
Samples enriched for “activated” stroma genes were further identified (n= 54)
based on the stroma signature derived from Moffitt et al.17 using the non-negative
matrix factorisation (NMF) consensus clustering66 (Extended Fig. 1d). Gene
signature for activated stroma seemed to be associated with an activated fibroblast
state. Within this set of activated stroma samples, the association between FAK
expression and OS was assessed using the procedure described above, accounting
for tumour stage (the only available clinical parameter in addition to OS).
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Differential analysis of epithelial gene expression. For the GEP data of tumour-
associated stroma, matched LCM epithelial samples and their GEP data were
available for 9 out of 10 low and 39 out of the 43 high stromal FAK samples (Finak
et al. dataset). This allowed us to perform the differential expression (DE) analysis in
the LCM epithelial compartment between low and high stroma FAK groups, to
determine the association between stroma FAK and epithelial gene expression
patterns. DE analysis in epithelial gene expression was performed using limma67,
and significantly differentially expressed probes/genes were identified using false
discovery rate (FDR) <0.05. The gene expression values, presented as the normalised
log-ratio of test RNA over reference RNA, for our top candidate genes were also
shown as box plots between low and high stromal FAK groups. The reference RNA
used in Finak et al. dataset was Universal Human Reference RNA (Stratagene, ID
#740000, La Jolla, California, USA). For the comparison of individual targets
between low and high stromal FAK patients, two-tailed Student’s t-test was used.
Pathway analysis. DE statistics derived from the limma test of epithelial gene
expression were further ranked based on log2 fold changes of low versus high
stroma FAK groups, and were used as input for the gene-set enrichment analysis
(GSEA) to identify dysregulated pathway gene sets curated in the Molecular Sig-
natures Database (v6.0)68. KEGG and Reactome gene sets were selected. Sig-
nificantly dysregulated pathways were identified (FDR < 0.1), and the network of
selected significant pathways was further constructed using the Cytoscape network
visualisation software, Enrichment Map69.
Proteomics and phosphoproteomics. For proteomics and phosphoproteomics
studies, cell lysis and trypsin digestion was performed as previously described70.
Phosphopeptides were enriched using TiO2 (GL Sciences)70. For phosphopro-
teomics, dried peptide pellets were resuspended in 9 µL of reconstitution buffer
(20 fmol/µL enolase digest in 3% ACN, 0.1% TFA) and 5.0 µL were loaded onto an
LC-MS/MS system consisting of a Dionex UltiMate 3000 RSLC directly coupled to
an Orbitrap Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific). For
proteomics, pellets were resuspended in reconstitution buffer (0.5 µg/µL) and 2 µL
were injected. The LC system used mobile phases A (3% ACN: 0.1% FA) and B
(100% ACN; 0.1% FA). Peptides were trapped in a μ-pre-column and separated in
a nanoflow analytical column. The following parameters were used: 3–28% B
gradient for 120 min and a flow rate of 0.25 µL/min. Eluting peptides were analysed
in a Q-Exactive Plus system with scan survey spectra (m/z 375–1500) was followed
by, data-dependent acquisition of the 15 most intense ions were selected for HCD
(higher energy collisional dissociation) and MS/MS scanning (200–2000m/z) with a
resolution of 17,500 FWHM. A 30 s dynamic exclusion period was enabled with 10
ppm mass window.
Peptide identification and quantification was carried out from the MS/MS and
MS data using the Mascot search engine as described before71. KSEA was carried
out by grouping peptides into substrate sets known to be phosphorylated by a
specific kinase38. Gene ontology enrichment analysis of proteins differentially
phosphorylated between conditions (at P < 0.05) was carried out using the
hypergeometric test72. For gene ontology analysis, we selected phosphopeptides
with P < 0.05. For KSEA we do not have a threshold for selection as the enrichment
is calculated using all detected phosphopeptides. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identifier PXD008276 and 10.6019/
PXD008276.
Statistical analysis. Results are presented as means ± s.e.m. for at least 2–3
independent experiments, unless otherwise stated. The sample sizes used were
based on level of changes and consistency expected. Statistical significance was
reported as appropriate. For animal experiments, animals were excluded from the
analysis if tumour volume breached the Home Office legal size limit. During
animal experiments, the investigator was blinded to the genotype of the animals
under study. For the tumour growth experiments, two-way ANOVA was used for
statistical analysis. For the remaining experiments, P values were calculated with
the two-tailed unpaired Student’s t-test unless otherwise stated. P < 0.05 was
considered statistically significant.
Ethical regulations. All procedures were approved by our local animal ethics
committee, Queen Mary University of London, and were executed in accordance
with United Kingdom Home Office regulations.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
For gene expression profiling (GEP), publicly available datasets were obtained and used,
GSE9014 and GSE2150. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD008276 and 10.6019/PXD008276 (https://www.ebi.ac.uk/pride/archive/
projects/PXD008276). All the relevant data that support the findings of this study are
available from the corresponding author on request.
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